BLA 761047 · Ultragenyx Pharm INC
Mepsevii
Vestronidase Alfa-Vjbk · Injection · Lysosomal beta Glucuronidase
NovelPriority reviewOrphanLast checked: Nov 20, 2026Latest source record: Dec 23, 2020 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2017
Nov 15, 2017
Approved uses
n/a
Original approval plus efficacy supplements
Registered trials
5
2 Phase 3, 1 recruiting
FAERS reports
0
0 serious, 0 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
No structured label for this application in openFDA. Older and discontinued products often have none.
Therapeutic areas: Rare and genetic disease
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
No approvals could be loaded from Drugs@FDA just now.
Clinical trials
Interventional ClinicalTrials.gov studies with "Vestronidase Alfa" as an intervention, any sponsor and status, largest first.
- A Study of UX003 Recombinant Human Beta-Glucuronidase (rhGUS) Enzyme Replacement Therapy in Subjects With Mucopolysaccharidosis Type 7, Sly Syndrome (MPS 7)Pivotal-lookingCompleted
Ultragenyx Pharmaceutical IncIndustry
NCT02432144 · 12 participants · Start Nov 10, 2015 · Primary completion Jan 14, 2019
Drug: UX003 · For: Sly Syndrome; MPS VII; Mucopolysaccharidosis and 1 more
Sites: Oakland, California; Orange, California; Minneapolis, Minnesota · 7 sites in all
- A Phase 3 Study of UX003 Recombinant Human Betaglucuronidase (rhGUS) Enzyme Replacement Therapy in Patients With Mucopolysaccharidosis Type 7 (MPS 7)Pivotal-lookingCompleted
Ultragenyx Pharmaceutical IncIndustry
NCT02230566 · 12 participants · Start Dec 2014 · Primary completion May 2016
Drug: UX003 · For: MPS 7; Sly Syndrome; Mucopolysaccharidosis and 1 more
Sites: Oakland, California; Orange, California; Miami, Florida · 4 sites in all
University of California, San FranciscoAcademic, hospital or other
NCT04532047 · 10 participants (planned) · Start Jul 1, 2021 · Primary completion Jul 31, 2031
Drug: Aldurazyme (laronidase) · For: MPS I; MPS II; MPS IVA and 6 more
Sites: San Francisco, California
Ultragenyx Pharmaceutical IncIndustry
NCT02418455 · 8 participants · Start Jul 21, 2015 · Primary completion Mar 26, 2019
Drug: UX003 · For: Sly Syndrome; MPS VII; Mucopolysaccharidosis and 1 more
Sites: Washington D.C., District of Columbia; New York, New York; Salt Lake City, Utah · 5 sites in all
Ultragenyx Pharmaceutical IncIndustry
NCT01856218 · 3 participants · Start Nov 2013 · Primary completion Jul 2016
Drug: UX003 · For: Mucopolysaccharidosis Type 7
Sites: Manchester, United Kingdom
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
No FAERS reports name this application.
FAERS reports by year
By the date FDA received the report.
No reports.
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part D: Mepsevii (Vestronidase Alfa-Vjbk)
2024 spending
$2.7M
Beneficiaries
n/a
20 claims
Per beneficiary
n/a
$557.96 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $0 |
| 2021 | $0 |
| 2022 | $0 |
| 2023 | $0 |
| 2024 | $2,678,222 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- A novel Blind Start study design to investigate vestronidase alfa for mucopolysaccharidosis VII, an ultra-rare genetic disease.
Harmatz P, Whitley CB, Wang RY, et al. · Mol Genet Metab 2018 · Clinical Trial, Phase III, Randomized Controlled Trial
- Long-term efficacy and safety of vestronidase alfa enzyme replacement therapy in pediatric subjects < 5 years with mucopolysaccharidosis VII.
Lau HA, Viskochil D, Tanpaiboon P, et al. · Mol Genet Metab 2022 · Clinical Trial, Phase II, Multicenter Study
- The long-term safety and efficacy of vestronidase alfa, rhGUS enzyme replacement therapy, in subjects with mucopolysaccharidosis VII.
Wang RY, da Silva Franco JF, López-Valdez J, et al. · Mol Genet Metab 2020 · Clinical Trial, Phase III, Randomized Controlled Trial
- Pharmacokinetic and Pharmacodynamic Modeling to Optimize the Dose of Vestronidase Alfa, an Enzyme Replacement Therapy for Treatment of Patients with Mucopolysaccharidosis Type VII: Results from Three Trials.
Qi Y, McKeever K, Taylor J, et al. · Clin Pharmacokinet 2019 · Clinical Trial, Phase I, Clinical Trial, Phase II
- Vestronidase alfa: Recombinant human β-glucuronidase as an enzyme replacement therapy for MPS VII.
Cadaoas J, Boyle G, Jungles S, et al. · Mol Genet Metab 2020 · Clinical Trial, Phase I, Clinical Trial, Phase II
Sponsor: Ultragenyx Pharm INC
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.